• 320 likes • 340 Views
Join Oddveig Myhre, a Naturopathic Medical Doctor, as she shares her experiences with the use of intravenous nutritional therapy in clinical practice. Discover the benefits, applications, and research behind this innovative treatment approach.
E N D
Tilskuddsparadiset USA:Erfaringer med bruk av tilskudd i klinisk praksis sammenlignet med Norge Vitamindagene, Sandvika 23.mars, 2019 Oddveig Myhre, Naturterapeut (Norge) Naturopathic Medical Doctor (USA), MS Neuroimmunology, MA Food Studies (USA)
Min utdannelse og erfaring • 1997: San Diego State University: BS Microbiology • 2002: Arizona State University: Masters of Science Microbiology/Neuroimmunology • 2005: Southwest College of Naturopathic Medicine and Health Sciences: Naturopathic Medical Doctor (NMD / ND) • Lege i USA med egen praksis (Phoenix Naturopathic Center i Scottsdale, AZ) • Lisens nr: 06935 • National Provider ID: 1386761443 • Skrevet 3 skolebøker for naturmedisin (med 2 kollegaer) • 2014: Chatham University, Pittsburgh: MA in Food Studies • Flyttet tilbake til Norge • Mars 2016 – Godkjent som Naturterapeut • Jobber hos Optimalhelse Senter Skien – OSS – som Naturterapeut. • www.velkommentiloss.no
Part I: Del 1: 5 deler – 4.5 timer Del 2: praktisk eksam Part II (embedseksamen): Går over 5 dager Del 1: Biomedical Science: 2 deler, hver på 2.5 timer Del 2: CoreClinical Science: 3 deler over 3 d, 3.5 t hver Del 3: ClinicalElectives: 3 deler, 1.5 time hver
Forskningskilder • Kilder: • US National Library of Medicine/ National Institutes of Health – PUBMED • PMID: 28682528 • Google Scholar • Referanser/Kilder oppgitt
Intravenøs ernæringsbehandling • Ernæring administrert rett inn i blodårer enten som et push (direkte fra sprøyte) eller fra bag (sterilt vann/Ringers/0.9% NaCl) • Premisser: • Når oral behandling ikke fungerer • Mye brukt med fordøyelsesproblemer • Når behandlingsdosen er høyere enn hva fordøyelsen tåler • Pasienten skal sjekkes for: • Serum chemistry profile with electrolytes (metabolisk panel/BMP) • Complete blood count (CBC) with differential • Complete urinalysis • Weight
Mest vanlige og populære intravenøse ernæringsbehandlinger • GlutathioneIV • Grå stær, grønn stær, alkoholisme, astma, kreft, hjerte og karsykdommer, høyt kolesterol, AIDs, ME, Alzheimers, osteoartrose, Parkinson’s, diabetes, COPD/KOLS, allergier, IBS, Crohn’sog redusert lever funksjon. • Alpha Lipoic Acid IV • diabetes, diabetes neuropathy, lever sykdommer, slag og andre nevrologiske sykdommer • ChelationIV • Calcium EDTA/disodiumEDTA – fjerner tungmetaller i kroppen (bly, kvikksølv), øker blodsirkulasjonen, høyt blodtrykk, CVD, demens, autisme, diabetes med mer
Mest vanlige og populære IV behandlinger • Rapid Mineral Replacement (RMR) IV • Øker mineraler og elektrolytter i kroppen – øker energi, ME, stress relaterte problemer, utmattelse, generell følelse av tretthet • Magnesium IV • Atrial eller ventrikulær arrhythmia (som resultat av hjerteinfarkt), astma, KOLS, nervesmerter, hypertensjon, PVCs, tretthet, fibromyalgi, ME og hjerte og karsykdommer • High-dose Vitamin CIV • For immunforsvaret, mot kreft, motvirke bivirkningene av cellegift og stråle behandling. • Brukes av Cancer Treatment Center of America hvor MD, DO og NMD jobber sammen
Høye doser av Vitamin C • For immunforsvaret • Ekstra tester: • Red blood cell G6PD (must be normal) • Glucose 6 phosphate dehydrogenase deficiency • Hemachromatose [1] Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH, Jr.: Phase I clinical trial of i.v. ascorbic acid in advancedmalignancy. Ann Oncol 2008, 19:1969-1974. [2] Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M: Pharmacologicascorbic acid concentrationsselectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. ProcNatlAcadSci U S A 2005, 20;102:13604-13609. [3] Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q: Pharmacologicascorbatesynergizeswithgemcitabine in preclinicalmodels of pancreatic cancer. Free RadicBiol Med 2011, 50:1610-1619. [4] Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M: Phase I evaluation of intravenousascorbic Acid in combination withgemcitabine and erlotinib in patientswithmetastaticpancreatic cancer. PLoS One 2012, 7:e29794.
Forskning • Mayland, C., Bennett, M. & Allan, K., 2005. Vitamin C deficiency in cancer patients. Palliat Med, Volume 19, pp. 17-20. • McCormick, W., 1959. Cancer: a collagen disease, secondary to nutrition deficiency. Arch. Pediatr., Volume 76, pp. 166-171. • Mikirova, N., Casciari, J. & Riordan, N., 2012. Ascorbateinhibition of angiogenesis in aortic rings ex vivo and subcutaneousMatrigelplugs in vivo. J Angiogenesis Res, Volume 2, pp. 2-6. • Mikirova, N., Casciari, J., Taylor, P. & Rogers, A., 2012. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Trans Med, Volume 10, pp. 189-99. • Mikirova, N., Ichim, T. & Riordan, N., 2008. Anti-angiogenic effect of high doses of ascorbic acid.. J Transl Med, Volume 6, p. 50. • Mikirova, N., Rogers, A., Casciari, J. & Taylor, P., 2012. Effects of high dose intravenousascorbic acid onthelevel of inflammation in patientswithrheumatoidarthritis. Mod Res Inflamm, Volume 1, pp. 26-32. • Moertel, C. et al., 1985. High-dose vitamin C versus placebo in the treatment of patientswithadvanced cancer who have no prior chemotherapy: a randomized double-blind comparison.. NEJM, Volume 312, pp. 137-41. • Monti, D. et al., 2012. Phase I evaluation of intravenousascorbic acid in combination withgemcitabine and erlotinib in patientswithmetastaticpancreatic cancer. PLoS One, Volume 7, p. e29794. • Murata, A., Morishige, F. & Yamaguchi, H., 1982. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Res Suppl, Volume 23, pp. 103-13. • Okunieff, P. & Suit, H., 1987. Toxicity, radiationsensitivitymodification, and combineddrugeffects of ascorbic acid withmisonidazole in vivo onFSaIImurinefirbosarcomas. JNCI, Volume 79, pp. 377-81. • Padayatti, S. et al., 2006. Intravenous vitamin C as a cancer therapy: three cases. CMAJ, Volume 174, pp. 937-42. • Padayatty, S. & Levine, M., 2000. Reevaluation of ascorbate in cancer treatment: emergingevidence, openminds and serendipity. J Am Coll Nutr., Volume 19, pp. 423-5. • Padayatty, S. et al., 2010. Vitamin C: intravenous use by complementary and alternative medical practitioners and adverseeffects. PLoS ONE, Volume 5, p. 11414. • Padayatty, S. et al., 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med., Volume 140, pp. 533-37. • Page, E. et al., 2007. Hypoxiaincudible factor-1 (alpha) stabilization in nonhypoxicconditions: role of oxidation and intracellualrascorbatedepletion. Mol Biol Cell, Volume 19, pp. 86-94. • Pollard, H., Levine, M., Eidelman, O. & Pollard, M., 2010. Pharmacologicalascorbic acid supressessyngenic tumor growth and metastases in hormone-refractory prostate cancer. In VIvo, Volume 2012, pp. 249-55. • Raloff, J., 2000. Antioxidantsmayhelp cancers thrive. Science News, Volume 157, p. 5. • Riordan, H. et al., 2005. A pilot clinicalstudy of continuousintravenousascorbate in terminal cancer patients. PR Health Sci J, Volume 24, pp. 269-76. • Riordan, H. et al., 2003. Intravenousascorbic acid: protocol for itsapplication and use. PR Health Sci. J., Volume 22, pp. 225-32. • Riordan, H., Jackson, J., Riordan, N. & Schultz, M., 1998. High-dose intravenous vitamin C in the treatment of a patient with renal cellcarcinoma of thekidney. J Ortho Med, Volume 13, pp. 72-3. • Riordan, N., JA, J. & Riordan, H., 1996. Intravenous vitamin C in a terminal cancer patient. J Ortho Med, Volume 11, pp. 80-2. • Riordan, N., Roirdan, H. & Meng, X., 1995. Intravenousascorbate as a tumor cytotoxicchemotherapeutic agent. Med Hypotheses, Volume 44, pp. 207-13. • Rivers, J., 1987. Safety of high-level vitamin C ingestion. In: Third Conference onAscorbic Acid. Ann NY AcadSci, Volume 489, pp. 95-102. • Shinozaki, K. et al., 2011. Ascorbic acid enhancesradiation-inducedapoptosis in an HL60 human leukemiacell line. J Ratiat Res, Volume 52, pp. 229-37. • Simone, C., Simone, N. S. V. & CB, S., 2007. Antioxidants and other nutrients do not inferferewithchemotherapy or radiation therapy and can increase survival, part 1. AtlernTher Health Med, Volume 13, pp. 22-8. • St. Sauver, J. et al., 2009. Associations betweeen c-reactive protein and benighprosaichyperplasialowerurinarytractoutcomes in a populationbasedcohort. Am J Epidemiol, Volume 169, pp. 1281-90. • Taper, H., Keyeux, A. & Roberfroid, M., 1996. Potentiation of radiotherapy by nontoxicpretreatmentwithcombined vitamins C and K3 in micebearing solid transplantable tumor. Anticancer Res, Volume 16, pp. 499-503. • Verrax, J. et al., 2004. Ascorbatepotentiatesthecytotoxicity of menadioneleading to an oxidative stress that kills cancer cells by a non-apoptotic capsase-3 independent form of celldeath. Apoptosis, Volume 9, pp. 223-33. • Verrax, J. & Calderon, P., 2009. Pharmacologicconcentrations of ascorbateareachieved by parenteral administration and exhibitantitumoraleffects. Free RadicBiol Med, Volume 47, pp. 32-40. • Vollbracht, C. et al., 2011. Intravenous vitamin C administrationimprovesquality of life in breastcacnerpatients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiologicalcohortstudy in Germany. In Vivo, Volume 82, pp. 983-90. • Wong, K. et al., 1994. Acute oxalatenephropathy after a massive intravenous dose of vitamin C. Aust ZN J Med, Volume 24, pp. 410-1. • Yeom, C., Jung, G. & Song, K., 2007. Changes of terminal cancer patietnshealthrelatedqualtiy of life after high dose vitamin C administration. Korean Med Sci, Volume 22, pp. 7-11. • Yeom, C. et al., 2009. High-dose concentrationadministration of ascorbic acid inhibits tumor growth in BALB/C miceimplantedwithsarcoma 180 cancer cells via therestriction of angiogenesis. J Transl Med, Volume 7, p. 70. • REFERENCES • Agus, D., Vera, J. & Golde, D., 1999. Stromalcelloxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., Volume 59, pp. 4555-8. • Ashino, H. et al., 2003. Novelfunction of ascorbic acid as an angiostaticfactor. Angiogenesis, Volume 6, pp. 259-69. • Belin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associatedwithinhibition of genes necessary to cellcycleprogression. PLoS ONE, Volume 4, p. e4409. • Benade, L., Howard, T. & Burk, D., 1969. Synergistic killing of Ehrlichascitescarcinomacells by ascorbate and 3-amino-1,2,4-triazole. Oncology, Volume 23, pp. 33-43. • Berlin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associatedwithinhibition of genes necessary for cellcycleprogression. PLoS ONE, Volume 4, pp. E44-0. • Block, K. et al., 2008. Impact of antioxidantsupplementaiononchemotherapeutic toxicity: a systematicreview of theevidence from randomizedcontrolled trials. Int J Cancer, Volume 123, pp. 1227-39. • Cameron, E. & Pauling, L., 1976. Supplemental ascorbate in thesupportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS USA, Volume 73, pp. 3685-9. • Cameron, E., Pauling, L. & Leibovitz, B., 1979. Ascorbic acid and cancer, a review. Cancer Res, Volume 39, pp. 663-81. • Campbell, A. & Jack, T., 1979. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J, Volume 24, p. 151. • Campbell, G., Steinberg, M. & Bower, J., 1975. Letter: ascorbic acid inducedhemolysis in a G-6-PD deficiency.. Ann Intern Med, Volume 82, p. 810. • Casciari, J., Riordan, H., Miranda-Massari, J. & Gonzalez, M., 2005. Effects of high dose of ascorbateadministrationon L-10 tumor growth in guineapigs. PRHSJ, Volume 24, pp. 145-50. • Casciari, J., Riordan, N. S. T. M. X., Jackson, J. & Riordan, H., 2001. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitrotumours. Br. J. Cancer, Volume 84, pp. 1544-50. • Chen, Q. et al., 2008. Pharmaologic doses of ascorbateact as a prooxidant and decreasegrowth of aggressive tumor xenografts in mice. PNAS USA, Volume 105, pp. 11105-9. • Chen, Q. et al., 2005. Pharmacologicascorbic acid concentrationsselectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS USA, Volume 205, pp. 13604-13609. • Creagan, E. et al., 1979. Failure of high-dose vitamin C (ascorbic acid) therapy to benefitpatientswithadvanced cancer: A controlled trial. NEJM, Volume 301, pp. 687-690. • Drisko, J., Chapman, J. & Hunter, V., 2003. The use of antioxidantswith first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr, Volume 22, pp. 118-23. • Du, J. et al., 2010. Mechanisms of ascorbate-inducedcytotoxicity in pancreatic cancer. Clin Cancer Res, Volume 16, pp. 509-20. • Espey, M. et al., 2011. Pharmacologicascorbatesynergizeswithgemcitabine in preclinicalmodels of pancreatic cancer. Free RadicBiol Med, Volume 50, pp. 1610-19. • Espey, M., Chen, Q. & Levine, M., 2009. Comment re: vitamin C antagonizesthecytotoxiceffects of chemotherapy. Cancer Research , Volume 69, p. 8830. • Frei, B. & Lawson, S., 2008. Vitamin C and cancer revisited. PNAC USA, Volume 105, pp. 11037-8. • Fromberg, A. et al., 2011. Ascorbateexerts anti-proliferativeeffectsthroughcellcycleinhibition and sensitizes tumor cellstowardcytostaticdrugs.. Cancer ChemotherPharmacol, Volume 67, pp. 1157-66. • Fujita, K. et al., 1982. Reduction of adriamycin toxicity by ascorbate in mice and guineapigs. Cancer Res, Volume 309-16, p. 42. • Geeraert, L., 2012. CAM-Cancer Consortium. Intravenoushigh-dose vitamin C. [Online] • Available at: http://www.cam-cancer.ort/CAM-Summaries/Other-CAM/Intravenous-high-dose-vitamin-C. • Ginter, E., Bobeck, P. & Vargova, D., 1979. Tissue levels and optimal dosage of vitamin C in guineapigs.. NutrMetab, Volume 27, pp. 217-26. • Gonzalez, M. et al., 2002. Inhibition of human breast cancer carcinomacellproliferation by ascorbate and copper.. PRHSJ, Volume 21, pp. 21-3.Heaney, M. et al., 2008. Vitamin C antagonizesthecytotoxiceffects of antineoplasticdrugs. Cancer Res., Volume 68, pp. 8031-8. • Henson, D., Block, G. & Levine, M., 1991. Ascorbic acid: biologicalfunctions and relation to cancer. JNCI, Volume 83, pp. 547-50. • Hoffer, L. et al., 208. Phase I clinical trial of i.v. ascorbic acid in advancedmalignancy. Ann Oncol, Volume 1969-74, p. 19. • Hoffman, F., 1985. Micronutrientrequirements of cancer patients.. Cancer, 55(Supl. 1), pp. 145-50. • Hornig, D., 1975. Distribution of ascorbic acid metabolites and analogues in man and animals. Ann NY AcadSci, Volume 258, pp. 103-18. • Jackson, J. & Hunninghake, R., 2006. False positive bloodglucosereadings after high-dose intravenous vitamin C. J Ortho Med, Volume 21, pp. 188-90. • Jackson, J., Riordan, H., Hunninghauke, R. & Riordan, N., 1995. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med, Volume 10, pp. 87-8. • Keith, M. & Pelletier, O., 1974. Ascorbic acid concentrations in leukocytes and selected organs of guineapigs in response to increasingascorbic acid intake. Am J ClinNutr, Volume 27, pp. 368-72. • Kuether, C., Telford, I. & Roe, J., 1988. The relation of thebloodlevel of ascorbic acid to tissue concentrations of this vitamin and thehistology of theincisorteeth in theguineapig. J Nutrition, Volume 28, pp. 347-58. • Kurbacher, C. et al., 1996. Ascorbic acid (vitamin C) improvestheantineoplasticactivity of doxorubicin, cisplatin, and paclitaxel in human breastcarcinomacells in vitro. Cancer Lett, Volume 103, pp. 183-9. • Levine, M. et al., 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommendeddietaryallowance. PNAS USA, Volume 93, pp. 3704-9. • Lin, A., Chen, K., Chung, H. & Chang, S., 2010. The significance of plasma c-reactive protein in patientswithelevated serum prostate-specific antigen levels. UrologicalSci, Volume 21, pp. 88-92.
De mest vanlige IV Cocktails • Meyer’s/Myers’ Cocktail • Mineral og vitamin blanding brukt for ME, tretthet, fibromyalgi, depresjon, muskel spasmer, astma, allergier/utslett, CHF/hjertesvikt (veldig sakte drypp!), angina, infeksjoner, og demens. Brukt for å forhindre forkjølelse og influensa, styrke immunforsvaret og øke energi. • Liver Detoxification – • glutathione, alphalipoic acid, hepar compositum and high dose vitamin C • Dr. Gallagher’s Cocktail – • Øke energi, forbedre enzym funksjoner og nerve funksjoner • vitamin c, glutathione, glyoxal compositum • Heart Health • magnesium, sporstoffer, cerecomp, vitaminer • Migraine • magnesium, riboflavin – kan gis som et push • HangoverRecovery Accelerator • Saline (0.9% NaCl), B vitaminer, vitamin C and glutathione.
Myers’ Cocktail • Utviklet av John Myers, MD • Begynte i 1954 • John Hopkins sykehus, Maryland • Alan Gaby, MD, treated thousands of patients with the Myers’ Cocktail over many years
Fibromyalgi – smerte behandling • 2 cc MgSO4 50% IV pushes: • Føles som om man blir fryktelig varm og tisser på seg …. • Traumeel – homeopatisk traume medisin i sterile ampuller • Methylkobalamin – hjelper ofte på energien
Enzymer og HCl Betaine Fordøyelsen: • HCl Betaine (400-800 mg/tab) • Din dose? Øk med 1 til brenning i magen • Først beskytt slimhinnen i magesekken • Lipase • For bruk av fordøyelse av fett /GB problematikk • Pepsin, trypsin, amylase, cellulase, protease, sukralase, laktase.….. • Super DigestAway– inneholder glutamin • Superzym • DPP IV • Bryter ned gluten og kasein • DPP IV inhibitors/Gliptins: DM2 • Wobenzyme (4-8 tab x 3-4/d akutt) • Betennelse og smerter, ledd problemer • Tysk produsert • Serrapeptase • Betennelse, smerter, etter kirurgi/traumer, blodpropper • Nattokinase • Blodpropper (bryter ned fibrinogen), CVD, kronisk bihulebetennelse, øker HDL • Super oxidedismutase (SOD) • Autoimmun reaksjoner PMID: 29896077 • Alzheimers, Parkinson • DiamineOxidase (DAO) • Histamin intolerance (HIT) syndromet
. Kilder "The story behindWobenzym". Wobenzym.com. Retrieved 2016-04-12. "Science". Wobenzym.com. Retrieved 2016-04-12 Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratiapeptidase in acute or chronic inflammation of otorhinolaryngologypathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res 1990;18:379-88.. Viewabstract. Nakamura S, Hashimoto Y, Mikami M, et al. Effect of theproteolyticenzymeserrapeptase in patientswithchronicairway disease. Respirology 2003;8:316-20.. Viewabstract. Shimizu H, Ueda M, Takai T, et al. A case of serratiopeptidase-inducedsubepidermalbullousdermatosis. J Int Med Res 1990;18:379-88.. Viewabstract. Tachibana M, Mizukoshi O, Harada Y, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomybuccalswelling. Pharmatherapeutica 1984;3:526-30.. Viewabstract. https://www.sciencedirect.com/topics/neuroscience/superoxide-dismutase AllergolInt. October 2017; 66 (4), 594-602 Doctor Murray 2018 IntegrBlood Press Control. 2016 October 13; 9: 95–104 Int J Mol Sci. Acta Haematol. 1990;84(3):139-43 BiolPharm Bull 1995 September;18(9):1194-6 Life Extension December 2016 Life Sci. 2003 July 25;73(10):1289-98 NutrRes. 2009 March;29(3):190-6 Angiology. 2003 September-October;54(5):531-9 Experimentia. 1987 October 15;43(10):1110-1 BioskiBiotechnolBiochem. 2013;77(2):392-4 Smart Publications Nattokinase — The Natural Blood Thinner The Baseline of Health Foundation 1999-2017 HumExpToxicol. 2013 July;32(7):721-35
Kjertelmedisin • 1925 textbook Medical Glandular Therapy was published as a joint project between the American Medical Association and the University of Chicago • Glandular Physiology and Therapy: Prepared Under the Auspices of the Council on Pharmacy and Chemistry of the American Medical Association • Astwood, E B et al 1955 • Aktive ingredienser: • Hormoner, enzymer • Næringsrik • Vitaminer, mineraler, aminosyrer, fettsyrer, DNA/RNA, polypeptider….. • Adaptogenisk effekt • Polypeptider påvirker hormoner • PMID: 22347152 • Sparer egne kjertler • (Hans Selye)
Stoffskifte - kjertelmedisin Blod test: fT3, fT4, TSH, anti TPO, anti TG, rT3 • Armour • Erfa • Naturethroid • Westhroid • WP Thyroid • Thyrolar • Compounded thyroid: • Apoteket lager blanding av T2, T3 og T4 spesifisert til pasientens behov
Binyre kjertelmedisin Test: Spytte test x 4 + 24 timers urin • Adrenal Cortex • Adrenal glandulars • Adrenal health • Adrenavive • Adrenal _______
Pankreas/Bukspyttkjertel kjertelmedisin • Pankreas • Diabetes – spesielt type 1 • Tidligere histore av pankreatisk sykdommer • Cystisk fibrose • Redusert pankreas funksjon • Kreft
Lever/GB kjertelmedisin • Ox bile (galle fra okse), Lipase • De som har fjernet GB • Får diare med feit mat • Lys avføring • Kvalm etter måltider • Tørr hud (lite opptak av fett)
Mild depresjon/Lavt stoffskifte/kroniske smerter • Tarmhelse- probiotika!! • Tester for nevrotransmittere i 24 timers urin • Mest vanlig mangler: • Dopamin: lite tiltak/lite energi/sitter fast i sofaen -Tyrosin • Serotonin: gråter mye, trist, søvn - 5HTP, Inositol • Gamma-aminobutyric acid; uro/angst, søvnforstyrrelser – GABA, Inositol? • Acetylcholine; lærevansker, hukommelse, mentalt trøtt, Alzheimers, demens, Parkinsons PMID: 23202919 • S-Adenosyl L-methionine (SAM-e) • Antidepressive effekt/smertelindring PMID: 28682528
Kilder • References: • Alzheimer’s disease medicationfactsheet. (n.d.). National InstituteonAging. Retrieved from http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-medications-fact-sheet • American Psychological Association. APA Concise Dictionary of Psychology. Washington, DC: American Psychological Association, 2009. Print. • Background to Parkinson’s Disease. (n.d.). Brown UniversityDivision of Biology and Medicine. Retrieved from http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/Neuroelectrodes_Team/background.html • Colman, A. M. (2006). Oxford Dictionary of Psychology. New York, NY: Oxford University Press. References • Tiwari, Prashant; Dwivedi, Shubhangi; Singh, MukeshPratap; Mishra, Rahul; Chandy, Anish (2017-05-15). "Basic and modernconceptsoncholinergicreceptor: A review". Asian Pacific Journal of Tropical Disease. 3 (5): 413–420. doi:10.1016/S2222-1808(13)60094-8. ISSN 2222-1808. PMC 4027320. • BaigAM, Rana Z, Tariq S, Lalani S, Ahmad HR (March 2018). "TracedontheTimeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote Acanthamoebaspp". ACS ChemNeurosci. 9 (3): 494–504. doi:10.1021/acschemneuro.7b00254. PMID 29058403. • BaigAM, Ahmad HR (June 2017). "Evidence of a M1-muscarinic GPCR homolog in unicellular eukaryotes: featuringAcanthamoebasppbioinformatics 3D-modelling and experimentations". J. Recept. Signal Transduct. Res. 37 (3): 267–275. doi:10.1080/10799893.2016.1217884. PMID 27601178. • SmythiesJ (2009). "Philosophy, perception, and neuroscience". Perception. 38 (5): 638–51. doi:10.1068/p6025. PMID 19662940. • SmythiesJ, d'Oreye de Lantremange M (2016). "The Nature and Function of Digital Information CompressionMechanisms in the Brain and in Digital Television Technology". Front SystNeurosci. 10: 40. doi:10.3389/fnsys.2016.00040. PMC 4858531. PMID 27199688. • Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Young WL, eds. (2009-01-01). Miller'sAnesthesia (7th ed.). Elsevier Health Sciences. pp. 343–47. ISBN 0-443-06959-X. • Kellogg DL, Zhao JL, Coey U, Green JV (February 2005). "Acetylcholine-inducedvasodilation is mediated by nitricoxide and prostaglandins in human skin". J. Appl. Physiol. 98 (2): 629–32. doi:10.1152/japplphysiol.00728.2004. PMID 15649880. • Jones BE (November 2005). "From waking to sleeping: neuronal and chemicalsubstrates". Trends Pharmacol. Sci. 26 (11): 578–86. doi:10.1016/j.tips.2005.09.009. PMID 16183137. • HimmelheberAM, Sarter M, Bruno JP (June 2000). "Increases in corticalacetylcholinerelease during sustainedattentionperformance in rats". Brain Res Cogn Brain Res. 9 (3): 313–25. doi:10.1016/S0926-6410(00)00012-4. PMID 10808142. • Ridley RM, Bowes PM, Baker HF, Crow TJ (1984). "An involvement of acetylcholine in objectdiscriminationlearning and memory in themarmoset". Neuropsychologia. 22 (3): 253–63. doi:10.1016/0028-3932(84)90073-3. PMID 6431311. • Francis PT, Palmer AM, Snape M, Wilcock GK (February 1999). "The cholinergichypothesis of Alzheimer's disease: a review of progress". J. Neurol. Neurosurg. Psychiatry. 66 (2): 137–47. doi:10.1136/jnnp.66.2.137. PMC 1736202. PMID 10071091. • Platt B, Riedel G (August 2011). "The cholinergic system, EEG and sleep". Behav. Brain Res. 221 (2): 499–504. doi:10.1016/j.bbr.2011.01.017. PMID 21238497. • Woolf NJ, Butcher LL (May 1986). "Cholinergic systems in the rat brain: III. Projections from thepontomesencephalictegmentum to the thalamus, tectum, basal ganglia, and basal forebrain". Brain Res. Bull. 16 (5): 603–37. doi:10.1016/0361-9230(86)90134-6. PMID 3742247. • Woolf NJ, Butcher LL (December 1989). "Cholinergic systems in the rat brain: IV. Descendingprojections of thepontomesencephalictegmentum". Brain Res. Bull. 23 (6): 519–40. doi:10.1016/0361-9230(89)90197-4. PMID 2611694. • GoldbergJA, Reynolds JN (December 2011). "Spontaneous firing and evoked pauses in thetonicallyactivecholinergicinterneurons of thestriatum". Neuroscience. 198: 27–43. doi:10.1016/j.neuroscience.2011.08.067. PMID 21925242. • Morris G, Arkadir D, Nevet A, Vaadia E, Bergman H (July 2004). "Coincident but distinctmessages of midbraindopamine and striatal tonicallyactive neurons". Neuron. 43 (1): 133–43. doi:10.1016/j.neuron.2004.06.012. PMID 15233923. • CrowTJ, Grove-White IG (October 1973). "An analysis of thelearning deficit followinghyoscineadministration to man". Br. J. Pharmacol. 49 (2): 322–7. doi:10.1111/j.1476-5381.1973.tb08379.x. PMC 1776392. PMID 4793334. • Ridley RM, Murray TK, Johnson JA, Baker HF (June 1986). "Learning impairmentfollowinglesion of the basal nucleus of Meynert in themarmoset: modification by cholinergicdrugs". Brain Res. 376 (1): 108–16. doi:10.1016/0006-8993(86)90904-2. PMID 3087582. • EastonA, Ridley RM, Baker HF, Gaffan D (July 2002). "Unilateral lesions of thecholinergic basal forebrain and fornix in onehemisphere and inferior temporal cortex in theoppositehemisphereproduce severe learningimpairments in rhesusmonkeys". Cereb. Cortex. 12 (7): 729–36. doi:10.1093/cercor/12.7.729. PMID 12050084. • Dean B (November 2009). "Evolution of the human CNS cholineric system: has thisresulted in theemergence of psychiatric disease?". Aust N Z J Psychiatry. 43 (11): 1016–28. doi:10.3109/00048670903270431. PMID 20001397.
DHEA- dehydroepiandrosterone • Teste binyrebark funksjonen • Overlevelseshormonet • Kvinner: 5-10 mg • Libido • Menn: 25-50 mg • Kan øke testosteron (+ Sink og MACA) • 7-keto DHEA 100-200 mg • Øker forbrenningen litt – ca 100 kalorier ekstra om dagen • Ingen effekt på sex hormonene (Likevel på WADA listen)
Progesteron • Blod eller spytte test • Skal ha en referanse verdi • Forholdet til østrogen er viktig • I USA solgt som tilskudd fordi de aller fleste er østrogen dominante • Wild Yam
Østrone/Østradiol/Østriol (E1, E2, E3) • Test: Blodprøve eller spytteprøve • Østrogen må være i balanse med progesteron • Må også være i balanse seg i mellom – EQ • Kan være med på å balanser autoimmun reaksjoner • Henry Lemon, MD – 40 års forskning på risiko for brystkreft • Jonathan Wright, MD, Seattle • Bio Identicalhormonespecialist • Reduser østrogen med: • DIM, I3C, Linfrø/Fiber….. • calcium-D-glucarate, milk thistle, choline, and taurine….
Behandlingsdoser av tilskudd tilgjengelig i Norge • N-acetyl cysteine: • 900 mg hver 3. time for forkjølelse/slim til tarm toleranse • 900 mg daglig for KOLS, astma, slim i lunger/tarmer, lever problemer/detox, røykere • Magnesium: Daglig 900-1200 mg • Ved mangler: • 400-600 mg hver 3. time til tarm toleranse • Formen på magnesium viktig: • Carbonate, oxid, hydroxid, malate,lactate, citrate, orotate, chelate, bisglycate, taurate • Malate – ME/Fibromyalgi • PMID: 25170357 • Vitamin C: Daglig 1-3 gram • Ved forkjølelse/influensa: • 3 gram hver 3. time til tarm toleranse • Vitamin D: Daglig 2000-3000 IU • Ved sykdom: 5-10000 IU hver 3. time • Ved mangler: • 10 000 IU daglig – test etter 1 måned • 50 000 IU IM + 5000 IU daglig – test etter 3 uker Til tarm toleranse – TTT: Til du får diare
Noen urter som jeg brukte i USA – restriksjoner på i Norge • Boswellia (Indisk frankincense) • Scutallerialateriflora – Praktskjoldbærer • Thujaoccidentalis • Piper methysticum /Kava Kava • Valarianaspp. • Eschscholziacalifornica/Kalifornia valmue/morfin • Ashwaganda/Indisk ginseng • HolyBasil (Tulsi)/Hellig basilikum • Ammivisnaga (Tannstikke) • Raowolfiaserpentina /Raovulfia/Indisk slangerot • Hawthorn/Crataegus/Hagtorn • Carditon – Ayush Herbs • Blodtrykkssenkende
Takk for oppmerksomheten! • Oddveig Myhre • Tlf: 95 48 02 38 • oddveig@velkommentiloss.no • Facebook: • Dr. Oddveig Myhre • Optimalhelse Senter Skien – OSS • www.velkommentiloss.no